Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Prophylactic broad spectrum antibiotics as a new anti-myeloma therapy.

Valkovic T, Nacinovic AD, Petranovic D.

Med Hypotheses. 2013 Dec;81(6):1137-40. doi: 10.1016/j.mehy.2013.10.021. Epub 2013 Oct 30.

PMID:
24238832
2.
3.

Toll-like receptors in human multiple myeloma: new insight into inflammation-related pathogenesis.

Abdi J, Garssen J, Redegeld F.

Curr Mol Med. 2014 May;14(4):423-31. Review.

PMID:
24730527
4.

The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma.

Abdi J, Engels F, Garssen J, Redegeld F.

Crit Rev Oncol Hematol. 2011 Nov;80(2):225-40. doi: 10.1016/j.critrevonc.2010.12.001. Epub 2011 Jan 13. Review.

PMID:
21236697
5.

Adhesion molecules--The lifelines of multiple myeloma cells.

Katz BZ.

Semin Cancer Biol. 2010 Jun;20(3):186-95. doi: 10.1016/j.semcancer.2010.04.003. Epub 2010 Apr 21. Review.

PMID:
20416379
6.

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.

Podar K, Richardson PG, Chauhan D, Anderson KC.

Expert Rev Anticancer Ther. 2007 Apr;7(4):551-66. Review.

PMID:
17428175
7.

Novel therapeutic targets in multiple myeloma.

Davies FE, Anderson KC.

Eur J Haematol. 2000 Jun;64(6):359-67. Review.

PMID:
10901589
8.

Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors.

Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C.

Leukemia. 2006 Jun;20(6):1130-7.

PMID:
16628189
9.

Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB.

Xu Y, Zhao Y, Huang H, Chen G, Wu X, Wang Y, Chang W, Zhu Z, Feng Y, Wu D.

Br J Haematol. 2010 Sep;150(5):543-53. doi: 10.1111/j.1365-2141.2010.08284.x. Epub 2010 Jul 14.

PMID:
20629663
10.

Immunodeficiency and immunotherapy in multiple myeloma.

Pratt G, Goodyear O, Moss P.

Br J Haematol. 2007 Sep;138(5):563-79. Review.

PMID:
17686051
11.

Prophylactic antibiotics for the prevention of early infection in multiple myeloma.

Oken MM, Pomeroy C, Weisdorf D, Bennett JM.

Am J Med. 1996 Jun;100(6):624-8.

PMID:
8678082
13.

Anti-tumour activity of bisphosphonates in human myeloma cells.

Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI.

Leuk Lymphoma. 1998 Dec;32(1-2):129-38. Review.

PMID:
10037008
14.
15.

Characteristics, pathogenesis, and novel treatments for multiple myeloma.

San Miguel J.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S1-4. Review.

PMID:
19791422
16.

Novel anti-myeloma agents and angiogenesis.

Anargyrou K, Dimopoulos MA, Sezer O, Terpos E.

Leuk Lymphoma. 2008 Apr;49(4):677-89. doi: 10.1080/10428190701861686. Review.

PMID:
18398734
17.

Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.

Anderson KC.

Exp Hematol. 2007 Apr;35(4 Suppl 1):155-62. Review.

PMID:
17379101
18.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
19.

Novel targeted therapies and combinations for the treatment of multiple myeloma.

Agarwal A, Mahadevan D.

Cardiovasc Hematol Disord Drug Targets. 2013 Mar 1;13(1):2-15. Review.

PMID:
22882073
20.

Plasma cell myeloma--new biological insights and advances in therapy.

Barlogie B, Epstein J, Selvanayagam P, Alexanian R.

Blood. 1989 Mar;73(4):865-79. Review.

Supplemental Content

Support Center